SPONSOR
LaNova Medicines Limited
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
LaNova Medicines Limited is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Malignant Tumors, Advanced Solid Tumours, Advanced Solid Tumor.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — LaNova Medicines Limited
How many clinical trials has LaNova Medicines Limited sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by LaNova Medicines Limited, of which 3 are actively recruiting participants. These trials cover conditions including Malignant Tumors, Advanced Solid Tumours, Advanced Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does LaNova Medicines Limited research focus on?
LaNova Medicines Limited clinical trials span Malignant Tumors, Advanced Solid Tumours, Advanced Solid Tumor. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a LaNova Medicines Limited clinical trial?
To participate in a LaNova Medicines Limited trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all LaNova Medicines Limited trials with current recruitment status updated daily.
Clinical Trials by LaNova Medicines Limited
NCT05615974 Phase 1, Phase 2
Recruiting
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Malignant Tumors
NCT06868199 Phase 1, Phase 2
Recruiting
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Advanced Solid Tumours
NCT06682780 Phase 1, Phase 2
Recruiting
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology